Douglas Lane & Associates LLC Trims Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Douglas Lane & Associates LLC decreased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 2.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,689,949 shares of the company's stock after selling 77,835 shares during the period. Douglas Lane & Associates LLC owned 0.75% of Elanco Animal Health worth $44,685,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Elanco Animal Health by 337.7% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company's stock worth $26,000 after acquiring an additional 1,361 shares during the period. ORG Wealth Partners LLC bought a new stake in shares of Elanco Animal Health during the third quarter valued at approximately $29,000. AM Squared Ltd purchased a new stake in Elanco Animal Health in the third quarter worth $34,000. Wilmington Savings Fund Society FSB bought a new position in Elanco Animal Health in the third quarter worth $35,000. Finally, Quarry LP purchased a new position in Elanco Animal Health during the second quarter valued at $40,000. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Down 2.3 %

NYSE ELAN traded down $0.27 during mid-day trading on Wednesday, reaching $11.53. The stock had a trading volume of 6,214,733 shares, compared to its average volume of 4,667,367. The company has a fifty day moving average price of $12.71 and a 200 day moving average price of $13.55. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a 1 year low of $11.28 and a 1 year high of $18.80. The stock has a market cap of $5.70 billion, a PE ratio of 28.83, a price-to-earnings-growth ratio of 2.03 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the company posted $0.18 earnings per share. The company's quarterly revenue was down 3.6% on a year-over-year basis. On average, research analysts expect that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of recent research reports. Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a research report on Monday, December 2nd. Leerink Partners assumed coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They issued a "market perform" rating and a $14.00 price objective on the stock. Barclays lifted their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, November 8th. Morgan Stanley downgraded Elanco Animal Health from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $17.00 to $15.00 in a research note on Thursday, September 19th. Finally, Stifel Nicolaus reduced their price objective on Elanco Animal Health from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Elanco Animal Health presently has an average rating of "Hold" and a consensus target price of $16.43.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.